AstraZeneca Capping Inhaler Costs for Eligible Customers at $35 From June 1

Published on March 19, 2024

United Kingdom-based pharmaceutical giant AstraZeneca has announced it will cap out-of-pocket costs for its inhalers across the United States at $35 for eligible patients. The big pharma company announced on March 18 that the cap will start from June 1 onward and apply to its entire range of inhaler products for asthma and chronic obstructive pulmonary disease, including Symbicort, Breztri Aerosphere, and Airsupra inhalers. Only people in the company’s savings programs are eligible, and government restrictions exclude people enrolled in federal government insurance programs. However, some uninsured or underinsured patients are eligible to take advantage of the new price. According to AstraZeneca’s Chief Executive Officer, Pascal Soriot, this is only the opening move in addressing a much larger issue. The CEO says Congress needs to come to the table and do its part....